Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) Income from Non-Controlling Interests (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Income from Non-Controlling Interests data on record, last reported at -$1.8 million in Q4 2023.

  • For Q4 2023, Income from Non-Controlling Interests fell 475.16% year-over-year to -$1.8 million; the TTM value through Dec 2023 reached -$1.9 million, up 3.96%, while the annual FY2024 figure was -$192000.0, 90.1% up from the prior year.
  • Income from Non-Controlling Interests reached -$1.8 million in Q4 2023 per CGEM's latest filing, down from -$179000.0 in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $1.5 million in Q1 2021 and bottomed at -$5.3 million in Q2 2020.
  • Average Income from Non-Controlling Interests over 4 years is -$966571.4, with a median of -$781500.0 recorded in 2020.
  • Peak YoY movement for Income from Non-Controlling Interests: skyrocketed 883.68% in 2021, then plummeted 475.16% in 2023.
  • A 4-year view of Income from Non-Controlling Interests shows it stood at -$760000.0 in 2020, then tumbled by 122.63% to -$1.7 million in 2021, then soared by 81.91% to -$306000.0 in 2022, then tumbled by 475.16% to -$1.8 million in 2023.
  • Per Business Quant database, its latest 3 readings for Income from Non-Controlling Interests were -$1.8 million in Q4 2023, -$179000.0 in Q1 2023, and -$306000.0 in Q4 2022.